Amgen (AMGN) Cash from Financing Activities (2009 - 2026)
Amgen (AMGN) posted quarterly Cash from Financing Activities of $1.4 billion for Q1 2026, up 134.96% year-over-year from $611.2 million in Q1 2025, and up 217.13% quarter-over-quarter from -$1.2 billion in Q4 2025.
Amgen (AMGN) Cash from Financing Activities (2009 - 2026) Analysis & Trends
Amgen's Cash from Financing Activities history runs 18 years deep, the most recent figure standing at $1.4 billion for Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 134.96% year-over-year to $1.4 billion; the TTM figure through Mar 2026 stood at -$5.3 billion (up 55.0% YoY), while the FY2025 annual figure was -$10.9 billion, down 15.34% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $1.4 billion, up from -$1.2 billion in the prior quarter.
- The five-year high for Cash from Financing Activities was $21.5 billion in Q1 2023, with the low at -$4.1 billion in Q1 2025.
- The 5-year median for Cash from Financing Activities is -$1.4 billion (2024), against an average of -$107.5 million.
- Peak annual rise in Cash from Financing Activities reached 712.09% in 2023, while the deepest fall reached 226.26% in 2023.
- Amgen's Cash from Financing Activities stood at -$1.0 billion in 2022, then soared by 362.54% to $2.8 billion in 2023, then slumped by 151.09% to -$1.4 billion in 2024, then climbed by 12.86% to -$1.2 billion in 2025, then jumped by 217.13% to $1.4 billion in 2026.
- Business Quant data shows AMGN's Cash from Financing Activities at $1.4 billion in Q1 2026, -$1.2 billion in Q4 2025, and -$2.9 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | -8.78 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | -5.05 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 1.76 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | -2.02 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | -3.89 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | -1.48 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 2.34 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -3.66 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | -2.10 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.48 Bn |
| Jun 30, 2026 | -1.48 Bn |
| Mar 31, 2026 | 1.44 Bn |
| Mar 31, 2026 | 1.44 Bn |
| Dec 31, 2025 | -1.23 Bn |
| Dec 31, 2025 | -1.23 Bn |
| Sep 30, 2025 | -2.85 Bn |
| Sep 30, 2025 | -2.85 Bn |
| Jun 30, 2025 | -2.67 Bn |
| Jun 30, 2025 | -2.67 Bn |
| Mar 31, 2025 | -4.11 Bn |
| Mar 31, 2025 | -4.11 Bn |
| Dec 31, 2024 | -1.41 Bn |
| Dec 31, 2024 | -1.41 Bn |
| Sep 30, 2024 | -3.65 Bn |
| Sep 30, 2024 | -3.65 Bn |
| Jun 30, 2024 | -2.65 Bn |
| Jun 30, 2024 | -2.65 Bn |
| Mar 31, 2024 | -1.71 Bn |
| Mar 31, 2024 | -1.71 Bn |